drug · antibody
margetuximab
Phase 2updated 3mo agoby TerSera Therapeutics LLC🔗 ChEMBL
Phase 2community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.
targets
Receptor tyrosine-protein kinase erbB-2
all catalysts(0)
nothing on the calendar yet
Trials studying margetuximab
- phase2MARGetuximab Or Trastuzumab (MARGOT)
- phase3Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
- phase3Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
- phase2Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
- phase2Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
- phase1Safety Study of MGAH22 in HER2-positive Carcinomas
- —Margetuximab Expanded Access Program
- phase1A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that